



6th EUROD Winter Meeting

Programme

January 19-21, 2023
Leuven, Belgium

EUROD
European Renal Osteodystrophy

 **CKD-MBD**
Chronic Kidney Disease Mineral
and Bone Disorder

Thursday, January 19, 2023

EUROD research forum

The EUROD research forum gathers basic and clinical researchers in CKD-MBD and focuses on scientific progress in renal bone disease. Novel research is presented through a mixture of invited mini lectures (ML) and selected free communications (FC) with ample time for discussion.

Chairs: Marie-Helene Lafage-Proust & Marc Vervloet

14:00 – 15:40 Research Forum Part 1

- 14:00 – 14:20 (ML): Assessment of calcium balance in CKD (**Rukshana Shroff**, London/United Kingdom)
- 14:20 – 14:40 (ML): Proton pump inhibitors and bone health (**Hanne Skou Jørgensen**, Aarhus/Denmark)
- 14:40 – 15:00 (FC): *To be determined*
- 15:00 – 15:20 (FC): *To be determined*
- 15:20 – 15:40 (ML): CaSR and Phosphate: spotlight on phosphate-sensing (**Mariano Rodriguez**, Cordoba/Spain)

15:40 – 16:10: Coffee break

16:10 – 17:50 Research Forum Part 2

- 16:10 – 16:30 (ML): Calciprotein particles at the interface of bone and vessels (**Andreas Pasch**, Bern/Switzerland)
- 16:30 – 16:50 (ML): CKD-MBD targets; a Pediatric Perspective? (**Justine Bacchetta**, Lyon/France)
- 16:50 – 17:10 (FC): *To be determined*
- 17:10 – 17:30 (ML): Calcium, vitamin D and skeletal health (**Geert Carmeliet**, Leuven/Belgium)
- 17:30 – 17:50 (FC): *To be determined*

17:50 – 18:00: Best Abstract Award (**Pieter Evenepoel**, Leuven/Belgium)

Friday, January 20, 2023

CME 1: Controversies in ROD: Calcium and magnesium in CKD – Friend or Foe

Exogenous **Ca** loading, especially through Ca-containing phosphate binders, is appointed a culprit of the vascular calcification in CKD-patients. This perception of Ca as a ‘vascular toxin’ triggered a war on Ca. As a consequence, CKD patients risk ending up with a negative Ca balance, with risk of osteoporosis. **Mg**, meanwhile, is experiencing a true Renaissance in CKD-MBD. Experimental and observational clinical data suggest that Mg may confer a survival benefit. As a consequence, Mg supplementation has gained much interest in clinic, but overzealous supplementation is not without risks. This CME provides an in depth discussion of current controversies regarding Ca and Mg supplementation in CKD.

10:30 – 10:45: Welcome and introduction (Pieter Evenepoel, Leuven/Belgium)

10:45 – 11:45 Session 1: Evolving concepts – what’s new

Chairs: Pieter Evenepoel & Nathalie Bravenboer

- 10:45 – 11:15 Update: Vascular calcification (**Markus Ketteler**, Stuttgart/Germany)
- 11:15 – 11:45 Update: Osteoporosis (**Renate de Jongh**, Amsterdam/The Netherlands)

Session 2: Ca and Mg homeostasis in health and CKD

Chairs: Anibal Ferreira & Justine Bacchetta

- 11:40 – 12:05 Essentials of Ca and Mg homeostasis in health (**Joost Hoenderop**, Nijmegen/The Netherlands)
- 12:05 – 12:30 Ca and Mg metabolism in CKD (**Lucile Figueres**, London/United Kingdom, Nantes/France)

12:30 – 13:20: Lunch

13:20 – 15:30: Session 3: Calcium in vascular/skeletal (patho) biology

Chairs: Mathias Haarhaus & Hanne Skou Jørgensen

- 13:20 – 13:40 Ca balance in CKD: positive, neutral, or negative? (**Pieter Evenepoel**, Leuven/ Belgium)
- 13:40 – 14:00 Ca – is there a bone-vascular link? (**Rukshana Shroff**, London/United Kingdom)
- 14:00 – 14:30 Ca supplementation in CKD: skeletal benefits outweigh vascular concerns (**Sandro Mazzaferro**, Rome/Italy)
- 14:30 – 15:00 Ca supplementation in CKD: vascular concerns outweigh skeletal benefits (**Antonio Bellasi**, Lugano/Switzerland)
- 15:00 – 15:30 Panel debate on Ca supplementation

15:30 – 16:00: Coffee break

16:00 – 17:15: Session 4: Mg and vascular/skeletal (patho) biology

Chairs: Sandro Mazzaferro & Syazrah Salam

- 16:00 – 16:30 Role of Mg in vascular and skeletal (patho)biology (**Iain Bressendorf**, Copenhagen/Denmark)
- 16:30 – 17:00 Mg supplementation in CKD: benefits and concerns (**Marc Vervloet**, Amsterdam/The Netherlands)
- 17:00 – 17:15 Panel debate on Mg supplementation

17:15 – 18:30: Network Meeting

20:00 – 22:30: Guided walk and dinner

Saturday, January 21, 2023

CME 2: The challenge of osteoporosis in CKD: balancing risks and benefits of common therapies

Osteoporosis is a state of bone fragility, where low bone mass and disrupted bone microarchitecture leads to an increased susceptibility of fracture. In CKD, a complex metabolic bone disease combines with traditional risk factors, multimorbidity, and polypharmacy leaving our patients at a particularly high risk. Lately, both our ability to identify patients at risk of fracture, and the pharmaceutical armamentarium to tackle bone fragility, has developed enormously. However, a huge treatment gap exists between those at risk and those receiving fracture-preventive treatment. The complex pathophysiology of bone fragility in CKD, coupled with lack of hard evidence, often leaves the physician in a state of therapeutic inertia. This session provides an update on assessment and treatment of osteoporosis in CKD.

Chairs: Jorge Cannata-Andia & Goce Spasovski

10:00 – 11:00: State-of-the art

- 10:00 – 10:30 Ca supplementation in CKD: report of the EUROD consensus meeting (**Pieter Evenepoel**, Leuven/Belgium & **Rukshana Shroff**, London/United Kingdom)
- 10:30 – 11:00 Denosumab or bisphosphonates in patients with advanced CKD and osteoporosis: balancing risks and benefits (**Mathias Haarhaus**, Stockholm/Sweden)

11:00 – 12:00: Case discussions

Panel: **Pieter Evenepoel, Mathias Haarhaus, Renate de Jongh**

- 11:00 – 12:00: Case-discussions in small groups, faculty act as facilitators
- 12:00 – 13:00: Panel debate of cases with input from audience

13:00 – 13:30: Closing remarks (Pieter Evenepoel, Leuven, Belgium)